Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Klebsiella pneumoniae glycoprotein

A glycoprotein complex extracted from Klebsiella pneumoniae K2O1 strain with immunostimulating property. This glycoprotein complex consists of 2 repetitive glycoprotein subunits; P1 comes from the bacterial capsule about 95 kD in molecular mass and F1, having an lipopolysaccharide-related structure (350 kDa), is derived from bacterial external membrane. Although the mechanism of action is not fully elucidated, Klebsiella pneumoniae F1 fraction appears to suppress monocyte apoptosis, hence inducing the differentiation of monocytes into macrophages. Furthermore, this agent also enhances humoral and cell-mediated immune responses, and increases natural killer cell cytotoxicity functions. This glycoprotein has been shown to reduce the incidence of infection.
US brand name:Biostim
Code name:RU 41.740
RU- 41740
Search NCI's Drug Dictionary